綠地香港(00337.HK)無錫合營公司引入太湖新城城市發展
綠地香港(00337.HK)公布,全資子公司東方康橋、寧波萬恆怡和企業管理及寧波潤泰企業管理訂立協議,為合營公司無錫綠坤房產開發引入新合營夥伴無錫太湖新城城市發展,共同就合營企業擁有的無錫市濱湖區目標土地進行物業開發項目。
簽訂合營協議前,合營企業由東方康橋擁有97%股權、由萬恆怡和擁有1.8%股權及由潤泰企業管理合營夥伴擁有1.2%股權。而引入太湖新城城市發展後,其將持股20%,而東方康橋則攤薄至77.6%,兩名原有合營夥伴共持股2.4%。
無錫綠坤房產開發註冊資本為2,100萬元人民幣,經已悉數出資,根據合營協議,新合營夥伴須向合營企業出資525萬元人民幣,作為增加註冊資本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.